(NASDAQ: ACAD) Acadia Pharmaceuticals's forecast annual revenue growth rate of 9.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Acadia Pharmaceuticals's revenue in 2025 is $996,283,000.On average, 9 Wall Street analysts forecast ACAD's revenue for 2025 to be $177,287,747,659, with the lowest ACAD revenue forecast at $175,242,920,564, and the highest ACAD revenue forecast at $179,153,999,660. On average, 9 Wall Street analysts forecast ACAD's revenue for 2026 to be $196,062,400,104, with the lowest ACAD revenue forecast at $188,054,470,258, and the highest ACAD revenue forecast at $209,873,434,773.
In 2027, ACAD is forecast to generate $221,359,143,883 in revenue, with the lowest revenue forecast at $198,246,806,984 and the highest revenue forecast at $234,149,271,260.